October 01, 2015

Washington, D.C. – October 1, 2015 – The COPD Foundation and ViiMed announced the launch of COPD360coach this week at the European Respiratory Society International Congress in Amsterdam. COPD360coach is the brainchild of a Crowdshaped event co-hosted by the COPD Foundation and Novartis Pharmaceuticals back in early June. The collaborative effort convened a diverse range of mindsets, knowledge backgrounds, and experiences in order to enhance patient-centered care for those affected by chronic obstructive pulmonary disease (COPD). COPD is a respiratory disease affecting approximately 30 million Americans and is the third leading cause of death in United States.

In order to bring the ideas from the open-thinking session to fruition, the COPD Foundation, the only U.S. healthcare nonprofit dedicated to preventing and curing COPD, conducted a nationwide technology search. They selected the innovative team at ViiMed, the leader in asynchronous telehealth and care coordination, to develop a solution combining what was derived from Crowdshaped into one, cohesive platform. Together, they are offering an exceptional platform for Health Systems and Accountable Care Organizations (ACO) to deploy to their patients in an effort to help patients better manage their disease.

Having been eagerly awaited since the project’s conception in mid-July, COPD360coach is an interactive website and mobile application for health coaching, health education, and wellness monitoring for patients with COPD. The platform complements and enhances healthcare organizations’ existing care management solutions by enabling a coordinated and asynchronous peer-coaching infrastructure. This approach further guides empowerment of people with COPD utilizing educational modules comprised of online videos and courses taught by health professionals and real COPD patients, all while providing an extended care coordination backbone for the Health System or ACO.

September 29, 2015

On September 19-21, 2015, the COPD Foundation partnered with Novartis Pharma and MIT Media Lab, Imperial College in London, and Technion: Israel Institute of Technology for the BREATHE Respiratory Hackathons. Over one weekend, innovators participated in a global event that took place simultaneously across three continents.

Each location fielded ten teams experienced in assorted disciplines, each examining and working with similar equipment. Teams were given free rein to explore solutions to many of the problems respiratory sufferers face daily.

Results of these efforts were presented at the European Respiratory Society Annual Meeting that took place in Amsterdam on September 26-28. Prizes were awarded to the top innovations.

September 28, 2015

Washington, D.C. – September 28, 2015 – The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), is excited to announce the launch of its most recent initiative: PRAXIS (Prevent and Reduce COPD Admissions through eXpertise and Innovation Sharing). The initiative is a result of the recommendations that were developed by experts and patient advocates that convened at the National Readmissions Summit held in Washington, D.C. in October of 2013. Sunovion Pharmaceuticals is the founding sponsor of PRAXIS.

PRAXIS is a robust collaborative and multidisciplinary effort to advance the scientific knowledge around ways to reduce COPD readmissions. The program’s mission is to prevent and reduce hospital admissions through expertise and innovation sharing, and aims to reduce the burden of COPD exacerbations and hospital readmissions by aligning the goals of families, patients, and providers with those of the CMS Hospital Readmissions Reduction Program. The initiative will enable the proactive identification and elimination of gaps in COPD care.

September 11, 2015

WASHINGTON, D.C. – September 11, 2015 – The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), in association with Novartis Pharma, will host three respiratory “hackathon” events, entitled Breathe Hackathons. The events will bring together designers, technicians, engineers, patients, physicians, and entrepreneurs to investigate solutions to many of the problems COPD patients face daily. COPD is a condition that affects an estimated 30 million Americans and over 250 million individuals worldwide. It is the third leading cause of death in the United States, and is characterized by increased wheezing and breathlessness.

Over two days in Boston, London, and Tel Aviv, innovators from around the world will meet to “hack” into medical equipment for respiratory use such as CPAP devices, nebulizers, oxygen concentrators, and sleep monitors in the hopes of integrating different solutions under a common platform to ultimately offer better health outcomes and improved quality of life for patients. These events will be held in three countries; September 19 and 20th at the Massachusetts Institute of Technology (MIT) Media Lab and at the Imperial College of Science and Technology, and on September 20 and 21st at Technion, the Israel Institute of Technology. Hackers from each school will be competing along with industry experts, COPD patients, and professionals in an effort to develop what could be the next big technology solution to a worldwide lung health epidemic.

September 11, 2015

LONDON, UK - September 11, 2015 - GlaxoSmithKline and Theravance, Inc. announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta®. The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation and either a history or increased risk of cardiovascular disease (CVD). The Study to Understand Mortality and MorbidITy (SUMMIT) in COPD is the first prospective study that aimed to understand the effect of respiratory treatments in patients with COPD and a history or risk of CVD.

Results demonstrated that while Breo Ellipta reduced the risk of all-cause mortality by 12.2 percent versus placebo, the difference was not statistically significant over the study period. Although the therapy reduced the rate of lung function decline by 8 millilitres per year compared to placebo, the companies said statistical significance could not be determined because Breo Ellipta failed to meet its primary endpoint. The drug was associated with a 7.4 percent lower risk of an on-treatment cardiovascular event versus placebo, which also was not a significant difference.

September 10, 2015

WASHINGTON, D.C. - September 10, 2015 - The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), is pleased to announce that it will host its first annual signature event, The Air Affair to Benefit the COPD Foundation on World COPD Day - November 18, 2015. The gala evening will be held at the American Museum of Natural History in New York City. Dr. Byron Thomashow will chair the Air Affair as the Foundation pays tribute to a special group of individuals and organizations who will be recognized for their contributions to the COPD community over the past year.

One of America's most endearing and enduring stars, Tony Orlando, will emcee the evening. Best known for his work as the lead singer of the group “Tony Orlando and Dawn”, Orlando rose to fame in the 1970s with major billboard hits including “Candida”, “Knock Three Times”, and “Tie a Yellow Ribbon Round the Ole Oak Tree.” Orlando will also treat guests of the Air Affair event to an exclusive performance.

July 23, 2015

WASHINGTON, D.C. - July 23, 2015 - The COPD Patient-Powered Research Network (COPD PPRN) led by the COPD Foundation (COPDF), announces today that it has been approved for a three-year $1.68 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) as part of the second phase of the development of PCORnet, the National Patient-Centered Clinical Research Network. This funding award continues PCORI's support for the COPD PPRN's participation in PCORnet, a large, collaborative research initiative designed to link researchers, patient communities, clinicians, and health systems in productive research partnerships that leverage the power of large volumes of health data maintained by the partner networks. PCORnet will enable the nation to conduct clinical research more quickly and less expensively than is now possible, and will ensure that research focuses on the questions and outcomes that matter most to patients and those who care for them.

PCORI provided $1.0 million to the COPD PPRN during the first phase of PCORnet’s development, which began in the spring of 2014.

As one of 34 health data networks that together make up this national clinical research resource in Phase II, the COPD PPRN is focused on expanding the COPD PPRN and furthering COPD research. The inclusion of patients is essential to success, and patients are involved in all aspects of the COPD PPRN. As the COPD PPRN moves into Phase II of PCORnet, our network is continuing to enroll individuals with COPD and individuals at risk for COPD into a registry with a scalable data hub for the purpose of supporting patient-driven, patient-centered outcomes research. Enrolled patients will represent the spectrum of COPD severity – most with multiple morbidities, across diverse geographic regions, broad age and socio-economic ranges, both genders, and all racial and ethnic groups.

July 09, 2015

WASHINGTON, D.C. - July 9, 2015 - The COPD Foundation is extremely pleased to announce that a new clinical biomarker, plasma fibrinogen, has been approved for use in interventional clinical trials in patients with chronic obstructive pulmonary disease, the nation’s 3rd leading cause of death. This is the first COPD biomarker to receive qualification by the U.S. Food and Drug Administration (FDA) and is the result of six years of work by the COPD Biomarker Qualification Consortium (CBQC).

The CBQC, which includes representatives and resources from university and government research, pharmaceutical and patient communities, was created by the COPD Foundation in 2010, with encouragement from the FDA and the National Heart, Lung and Blood Institute, to develop a “biomarker qualification process” for COPD. Biomarkers are medical processes that researchers use to measure disease severity or to determine if a new drug or treatment is effective. Being able to use a biomarker qualified by the FDA assures drug developers that any potential new drug applications will not be rejected simply because of how the drug’s efficacy was measured or how patients were selected.

“This is a major triumph and, on behalf of the entire COPD community, I extend a heart-felt thank you to the FDA and congratulate the CBQC on its commitment and tireless leadership that allowed us to reach this significant milestone,” said John W. Walsh, co-founder and president of the COPD Foundation. “Individuals working in the pharmaceutical industry, universities and the patient community have spent several million dollars and countless hours assembling and analyzing data that has led to the FDA’s monumental decision to approve this first COPD biomarker. Ultimately this clinical biomarker will enable future drug development to benefit patients.”

May 28, 2015

WASHINGTON, D.C./CHICAGO – May 28, 2015 –The COPD Foundation will host COPD9USA, June 5-6, 2015, at Hyatt Regency O’Hare, Chicago. The event will focus on chronic obstructive pulmonary disease (COPD), the nation's third leading cause of death, providing clinical and scientific knowledge for physicians, nurses, respiratory therapists and anyone involved with the management of individuals with COPD.

"COPD9USA is a unique opportunity to interact face-to-face with thought-leaders in the field and to share practical information for care management, as well as the latest in clinical research,” says John W. Walsh, president and co-founder of the COPD Foundation.

The conference will highlight cutting-edge issues that affect patient care from research, clinical, and care delivery perspectives.

May 07, 2015

WASHINGTON, D.C. – May 7, 2015 – The COPD Foundation released today a video animation, “A Dog’s Life,” to promote awareness and education about chronic obstructive pulmonary disease (COPD), a spectrum of inflammatory lung diseases that include chronic bronchitis and emphysema. Patients with COPD experience chronic respiratory symptoms such as difficulty breathing, wheezing, and coughing.

“A Dog’s Life,” created by Novartis, depicts the daily struggles of life with COPD from the perspective of a patient’s pet. The animated short follows a dog and his owner whose health and untreated symptoms worsen over time. The patient’s quality of life improves once he is introduced to the COPD Foundation’s educational resources and community, COPD360social.org, a unique social networking website for individuals whose lives are affected by COPD.

Page 1 of 20First   Previous   [1]  2  3  4  5  6  7  8  9  10  Next   Last   

Join Us on COPD360social

Sign In to Participate
Or register to become a member

Search Press Releases

12 Million Don't Know